CLAIMS

What is claimed is:

		1.	An isolated nucleic acid molecule comprising a polynucleotide having a
	sequence selec	cted fro	m the group consisting of
		(a)	a sequence encoding amino acids from about 1 to about 744 of SEQ ID
	NO:3;		
		(b)	a sequence encoding amino acids from about 2 to about 744 of SEQ ID
	NO:3;		
		(c)	a sequence encoding amino acids from about 1 to about 691 of SEQ ID
	NO:6;		
		(d)	a sequence encoding amino acids from about 2 to about 691 of SEQ ID
	NO:6;		
		(e)	a sequence encoding amino acids from about 1 to about 724 of SEQ ID
	NO:9;		
	Λ	(f)	a sequence encoding amino acids from about 2 to about 724 of SEQ ID
	NO:9;		
		(g)	a sequence encoding amino acids from about 1 to about 795 of SEQ ID
	NO:12;		
		(h)	a sequence encoding amino acids from about 2 to about 795 of SEQ ID
	NO:12;	1	
		(i) /	complements of the sequences of (a)-(h);
		(i) /	a sequence having 50-2232 contiguous nucleotides from the coding region
	of SEQ ID NO	<i>[</i>	
	•	(k)	a sequence having 50-2073 contiguous nucleotides from the coding region
	of SEQ ID NO). 4;	
	`	$\int_{(1)}$	a sequence having 50-2172 contiguous nucleotides from the coding region
		Γ^*	

- (m) a sequence having 50-2385 contiguous nucleotides from the coding region of SEQ ID NO:10;
 - (n) sequences having at least 90% identity to the sequences of (a) (m);
- (o) sequences having 100-1500 contiguous nucleotides from the coding region SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 or SEQ ID NO:10;
- (p) sequences having 500-1000 contiguous nucleotides from the coding region of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 or SEQ ID NO:10;
- (r) sequences of (a) (h), except for at least one amino acid substitution in the encoded amino acid sequence; and
- (s) sequences of (a) (h), expect for a conversion of a conserved lysine to an alanine at an ATP binding site of the encoded amino acid sequence.
- 2. A method of making a vector comprising inserting a nucleic acid molecule of claim 1 into said vector in operable linkage to a promoter.
 - 3. A vector produced by the method of claim 2.
- 4. A method of making a host cell comprising transforming or transfecting a vector of claim 3 into a cell.
 - 5. A host cell produced by the method of claim 4.
- 6. A method of making a polypeptide, comprising culturing the host cell of claim 5 under conditions such that said polypeptide is expressed and recovering said polypeptide.



- 7. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - (a) sequences having at least 95% identity to an amino acid sequence of:
 - (i) amino acids from about 1 to about 744 of SEQ ID NO:3,
 - (ii) amino acids from about 2 to about 744 of SEQ ID NO:3,
 - (iii) amino acids from about 1 to about 691 of SEQ ID NO:6,
 - (iv) amino acids from about 2 to about 691 of SEQ ID NO:6,
 - (v) amino acids from about 1 to about 724 of SEQ ID NO:9,
 - (vi) amino acids from about 2 to about 724 of SEQ ID NO:9,
 - (vii) amino acids from about 1 to about 795 of SEQ ID NO:12, or
 - (viii) amino acids from about 2 to about 795 of SEQ ID NO:12;
- (b) sequences having, expect for at least one amino acid substitution, an amino acid sequence of: (i) (viii);
- (c) sequences having, expect for at least one amino acid substitution, an amino acid sequence of: (i) (viii); and
- (d) sequences having, expect for a conversion of a conserved lysine to an alanine at the ATP binding site of said polypeptide, an amino acid sequence of: (i) (viii).
- 8. An epitope-bearing portion of a polypeptide selected from the group consisting of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9 and SEQ ID NO:12.
- 9. The epitope-bearing portion of claim 8, which comprises about 5 to about 50 contiguous amino acids.
 - 10. An isolated antibody that binds to the polypeptide of claim 7.
 - 11. A complex comprising a polypeptide of claim 7 and a Dishevelled protein.

- 12. A complex comprising a fragment of a polypeptide of claim 7 and a Dishevelled protein.
- 13. A method of identifying an inhibitor or enhancer of PAR-1 phosphorylation activity, comprising:
 - (a) contacting a cell transfected with at least an expression vector encoding Wnt with a candidate inhibitor or enhancer; and
 - (b) detecting an increase or decrease in Dsh phosphorylation,

wherein a decrease in Dsh phosphorylation indicates the presence of an inhibitor and an increase in Dsh phosphorylation indicates the presence of an enhancer.

- 14. An isolated PAR-1 modulator selected from the group consisting of an antisense oligonucleotide, a ribozyme, a protein, a polypeptide, and a small molecule.
- 15. The isolated PAR-1 modulator of claim 14, wherein said PAR-1 modulator is an antisense molecule or the complement thereof.
- 16. The isolated PAR-1 modulator of claim 15, wherein said antisense molecule or the complement thereof has at least 15 consecutive nucleic acids of the sequence of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9 or SEQ ID NO:12 or which hybridizes under high stringency conditions to said at least 15 consecutive nucleic acids of the sequence of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9 or SEQ ID NO:12.
- 17. The isolated PAR-1 modulator of claim 15, wherein said antisense molecule is selected from the group consisting of SEQ ID NO:13, SEQ ID NO:15 and SEQ ID NO:17.

- 18. The isolated PAR-1 modulator of claim 14, wherein said PAR-1 modulator is selected from the group consisting of an antibody and an antibody fragment.
- 19. The isolated PAR-1 modulator of claim 14, wherein said polypeptide has an amino sequence with at least 95% identity to the amino acid sequence provided in SEQ ID NO:22.
- 20. A composition, comprising a therapeutically effective amount of a PAR-1 modulator of claim 14 in a pharmaceutically acceptable carrier.
- 21. A method of treating a mammal with a disease or disorder associated with a PAR-1 polypeptide, comprising administering to the mammal a composition including a therapeutically effective amount of a PAR-1 modulator of claim 14.
- 22. The method of claim 23, wherein said PAR-1 modulator is an antisense molecule is selected from the group consisting of SEQ ID NO:13, SEQ ID NO:15 and SEQ ID NO:17.
- 23. The method of claim 21, wherein said PAR-1 modulator is a polypeptide that has an amino sequence with at least 95% identity to the amino acid sequence provided in SEQ ID NO:22.
- 24. The method of claim 21, wherein said PAR-1 modulator is selected from the group consisting of an antibody and an antibody fragment.
- 25. The method of claim 21, wherein said PAR-1 modulator is administered ex vivo to said mammalian cell.